Paper34201655
MHC Class I Deficiency in Solid Tumors and Therapeutic Strategies to Overcome It.
Shklovskaya E and 1 other. Int J Mol Sci, 2021. Cited by 58 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. MHC Class I Deficiency in Solid Tumors and Therapeutic Strategies to Overcome It. Papers, record 34201655. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34201655
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antigens, Neoplasm | Major topic |
| Histocompatibility Antigens Class I | Major topic |
| Neoplasms | Major topic |
| Tumor Escape | Major topic |
| Animals | |
| CD4-Positive T-Lymphocytes | |
| Down-Regulation | |
| Humans | |
| Immunotherapy | |
| Killer Cells, Natural | |
| Mutation |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 1128951; 1130423 | National Health and Medical Research Council of Australia | PubMed |
Source PubMed
References347
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 10,727,458 | Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer. | J Exp Med | 2000 | https://conductscience.org/library/papers/10727458 | PubMed |
| 2 | 31,810,126 | Comprehensive characterization of tumor infiltrating natural killer cells and clinical significance in hepatocellular carcinoma based on gene expression profiles. | Biomed Pharmacother | 2020 | https://conductscience.org/library/papers/31810126 | PubMed |
| 3 | 28,512,174 | Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma. | Clin Cancer Res | 2017 | https://conductscience.org/library/papers/28512174 | PubMed |
| 4 | 11,117,911 | Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. | Lancet | 2000 | https://conductscience.org/library/papers/11117911 | PubMed |
| 5 | 32,524,362 | IL-6-induced CD39 expression on tumor-infiltrating NK cells predicts poor prognosis in esophageal squamous cell carcinoma. | Cancer Immunol Immunother | 2020 | https://conductscience.org/library/papers/32524362 | PubMed |
| 6 | 22,645,137 | Regulation of class I major histocompatibility complex (MHC) by nucleotide-binding domain, leucine-rich repeat-containing (NLR) proteins. | J Biol Chem | 2012 | https://conductscience.org/library/papers/22645137 | PubMed |
| 7 | 28,983,798 | Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience. | Adv Ther | 2017 | https://conductscience.org/library/papers/28983798 | PubMed |
| 8 | 29,301,958 | A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing. | Science | 2018 | https://conductscience.org/library/papers/29301958 | PubMed |
| 9 | 19,883,394 | Hypermethylation of HLA class I gene is associated with HLA class I down-regulation in human gastric cancer. | Tissue Antigens | 2010 | https://conductscience.org/library/papers/19883394 | PubMed |
| 10 | 32,355,214 | Transcriptional Upregulation of NLRC5 by Radiation Drives STING- and Interferon-Independent MHC-I Expression on Cancer Cells and T Cell Cytotoxicity. | Sci Rep | 2020 | https://conductscience.org/library/papers/32355214 | PubMed |
| 11 | 22,383,801 | Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity. | Blood | 2012 | https://conductscience.org/library/papers/22383801 | PubMed |
| 12 | 29,388,200 | Phase I clinical trial of adoptive transfer of expanded natural killer cells in combination with IgG1 antibody in patients with gastric or colorectal cancer. | Int J Cancer | 2018 | https://conductscience.org/library/papers/29388200 | PubMed |
| 13 | 28,408,606 | Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer. | Science | 2017 | https://conductscience.org/library/papers/28408606 | PubMed |
| 14 | 10,894,167 | CD4+ T cell--mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. | Immunity | 2000 | https://conductscience.org/library/papers/10894167 | PubMed |
| 15 | 20,625,726 | The escape of cancer from T lymphocytes: immunoselection of MHC class I loss variants harboring structural-irreversible "hard" lesions. | Cancer Immunol Immunother | 2010 | https://conductscience.org/library/papers/20625726 | PubMed |
| 16 | 19,002,680 | NetMHCpan, a method for MHC class I binding prediction beyond humans. | Immunogenetics | 2009 | https://conductscience.org/library/papers/19002680 | PubMed |
| 17 | 31,564,637 | An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer. | Cancer Cell | 2019 | https://conductscience.org/library/papers/31564637 | PubMed |
| 18 | 33,827,917 | Epigenetic reprogramming of tumor cell-intrinsic STING function sculpts antigenicity and T cell recognition of melanoma. | Proc Natl Acad Sci U S A | 2021 | https://conductscience.org/library/papers/33827917 | PubMed |
| 19 | 25,409,260 | Genetic basis for clinical response to CTLA-4 blockade in melanoma. | N Engl J Med | 2014 | https://conductscience.org/library/papers/25409260 | PubMed |
| 20 | 29,107,330 | Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. | Cell | 2017 | https://conductscience.org/library/papers/29107330 | PubMed |
Cited by47
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 58 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,985,562 | HLA class I and II polymorphisms in pediatric neuroblastoma: mechanistic links to immune surveillance, tumor evolution, and clinical translation. | Front Genet | 2026 | https://conductscience.org/library/papers/42985562 | PubMed |
| 42,954,362 | Neoadjuvant Therapy for Non-Small Cell Lung Cancer: Recent Advances and Future Directions. | Cancer Med | 2026 | https://conductscience.org/library/papers/42954362 | PubMed |
| 42,798,230 | Selinexor potentiates NK cell activation against multiple myeloma. | Clin Exp Immunol | 2026 | https://conductscience.org/library/papers/42798230 | PubMed |
| 42,588,678 | The Central Role of HLA Class II-Restricted Helper Neoantigen Vaccines in Cancer Immunotherapy. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42588678 | PubMed |
| 42,346,099 | The Architecture of Immune Escape in Neuroblastoma: Plasticity, Silence and Escape Engineer Immune Blindness. | Cells | 2026 | https://conductscience.org/library/papers/42346099 | PubMed |
| 42,331,945 | Two-way tuning of the decidual natural killer cells and recurrent pregnancy loss. | Sci Rep | 2026 | https://conductscience.org/library/papers/42331945 | PubMed |
| 42,287,670 | Role of the Proteasome System in Shaping Cellular Immunological Characteristics and Its Impact in Modulating the Pathogenesis of Immune-Related Diseases. | Cells Tissues Organs | 2026 | https://conductscience.org/library/papers/42287670 | PubMed |
| 41,750,317 | Advances in Next-Generation Immunotherapies for Ovarian Cancer: Mechanisms of Immune Evasion and Novel Therapeutic Targets. | Biomolecules | 2026 | https://conductscience.org/library/papers/41750317 | PubMed |
| 41,437,275 | Cancer vaccine overcomes immune evasion of nasopharyngeal carcinoma by restoring MHC-I through transcriptional regulation of NLRC5. | J Transl Med | 2025 | https://conductscience.org/library/papers/41437275 | PubMed |
| 41,410,712 | Gut microbial metabolite butyrate boosts p53-expressing telomerase-specific oncolytic adenovirus efficacy by enhancing infectivity and activating MHC-I/cGAS-STING. | Cancer Immunol Immunother | 2025 | https://conductscience.org/library/papers/41410712 | PubMed |
| 41,346,595 | Immune checkpoint inhibitors in melanoma: mechanisms, immune cell interactions, and the tumour microenvironment. | Front Immunol | 2025 | https://conductscience.org/library/papers/41346595 | PubMed |
| 41,292,152 | Tumor Microenvironments in Malignant Ovarian Germ Cell Tumors: MHC Class I Loss and T-Cell Exhaustion in Dysgerminoma. | Cancer Sci | 2026 | https://conductscience.org/library/papers/41292152 | PubMed |
| 41,258,335 | Targeting prostate adenocarcinoma tumor microenvironment via cancer nanotheranostics: a comprehensive update on improved roadmap for disease diagnosis, therapy and management. | Clin Transl Oncol | 2026 | https://conductscience.org/library/papers/41258335 | PubMed |
| 40,673,641 | Decoding MHC loss: Molecular mechanisms and implications for immune resistance in cancer. | Clin Transl Med | 2025 | https://conductscience.org/library/papers/40673641 | PubMed |
| 40,575,168 | The efficacy and safety of chemoimmunotherapy in patients with MSI-L/MSS/pMMR status metastatic colorectal cancer: a systematic review and meta-analysis of randomized controlled trials. | Front Oncol | 2025 | https://conductscience.org/library/papers/40575168 | PubMed |
| 40,431,665 | Classification of the LC4 Primarily-like Cell Line-Recapitulating a CDK4 Overexpressing Immune Evasive HIV-HCV-Induced HCC. | Viruses | 2025 | https://conductscience.org/library/papers/40431665 | PubMed |
| 40,269,245 | Fangchinoline-mediated autophagy inhibition amplifies antigen presentation and PD-1 blockade efficacy in lung cancer. | Acta Pharmacol Sin | 2025 | https://conductscience.org/library/papers/40269245 | PubMed |
| 40,227,782 | Beyond Adaptive Immunity: Trained Innate Immune Responses as a Novel Frontier in Hepatocellular Carcinoma Therapy. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/40227782 | PubMed |
| 40,098,955 | The potential applications of peptide-loading complex in cancer treatment. | Front Immunol | 2025 | https://conductscience.org/library/papers/40098955 | PubMed |
| 39,879,294 | One-dimensional nanosonosensitizer boosted multiple branches of immune responses against MHC-deficient immune-evasive urologic tumor. | Sci Adv | 2025 | https://conductscience.org/library/papers/39879294 | PubMed |
Genes79
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/34201655
GET https://conductscience.org/api/papers/v1/34201655/references?page=2